Identification of the molecular basis of doxorubicin-induced cardiotoxicity

被引:1411
|
作者
Zhang, Sui [1 ]
Liu, Xiaobing [2 ,3 ]
Bawa-Khalfe, Tasneem [1 ]
Lu, Long-Sheng [2 ]
Lyu, Yi Lisa [4 ]
Liu, Leroy F. [4 ]
Yeh, Edward T. H. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA
[2] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA
[3] Shanghai Jiao Tong Univ, Dept Vasc Surg, Peoples Hosp 9, Sch Med, Shanghai 200030, Peoples R China
[4] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
基金
美国国家卫生研究院;
关键词
TOPOISOMERASE-II-BETA; INDUCED CARDIOMYOPATHY; HEART; GENE; TRANSCRIPTION; EXPRESSION; PREVENTION; PGC-1-BETA; APOPTOSIS; ADULT;
D O I
10.1038/nm.2919
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS). Here we show that cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-II beta) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Furthermore, cardiomyocyte-specific deletion of Top2b protects mice from the development of doxorubicin-induced progressive heart failure, suggesting that doxorubicin-induced cardiotoxicity is mediated by topoisomerase-II beta in cardiomyocytes.
引用
收藏
页码:1639 / +
页数:7
相关论文
共 50 条
  • [31] Myofilament changes in doxorubicin-induced cardiotoxicity
    Goncalves Rodrigues, P.
    Miranda-Silva, D.
    Barros, C.
    Hamdani, N.
    Linke, W.
    Leite-Moreira, A. F.
    Falcao-Pires, I.
    EUROPEAN HEART JOURNAL, 2015, 36 : 897 - 897
  • [32] THE ROLE OF AUTOPHAGY IN DOXORUBICIN-INDUCED CARDIOTOXICITY
    Coleman, J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2011, 59 (02) : 479 - 479
  • [33] Doxorubicin-induced apoptosis: Implications in cardiotoxicity
    B. Kalyanaraman
    Joy Joseph
    Shashi Kalivendi
    Suwei Wang
    Eugene Konorev
    Srigiridhar Kotamraju
    Molecular and Cellular Biochemistry, 2002, 234-235 : 119 - 124
  • [34] Fighting doxorubicin-induced cardiotoxicity with adiponectin
    McTiernan, Charles F.
    CARDIOVASCULAR RESEARCH, 2011, 89 (02) : 262 - 264
  • [35] Molecular mechanisms involved in doxorubicin-induced cardiotoxicity: A bibliometrics analysis by VOSviewer
    Fatemeh Yarmohammadi
    A. Wallace Hayes
    Gholamreza Karimi
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 1971 - 1984
  • [36] Molecular mechanisms involved in doxorubicin-induced cardiotoxicity: A bibliometrics analysis by VOSviewer
    Yarmohammadi, Fatemeh
    Hayes, A. Wallace
    Karimi, Gholamreza
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (04) : 1971 - 1984
  • [37] Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
    Lin, Xiaoxiao
    Wu, Guomin
    Wang, Shuai
    Huang, Jinyu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] MicroRNA in the Diagnosis and Treatment of Doxorubicin-Induced Cardiotoxicity
    Kuang, Ziyu
    Wu, Jingyuan
    Tan, Ying
    Zhu, Guanghui
    Li, Jie
    Wu, Min
    BIOMOLECULES, 2023, 13 (03)
  • [39] Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
    Liu, Hao
    Wang, Haiyan
    Xiang, Dingcheng
    Guo, Wangang
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2017, 17 (01) : 44 - 50
  • [40] Protectors against doxorubicin-induced cardiotoxicity: Flavonoids
    A. Bast
    H. Kaiserová
    G. J. M. den Hartog
    G. R. M. M. Haenen
    W. J. F. van der Vijgh1
    Cell Biology and Toxicology, 2007, 23 : 39 - 47